pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma
Ningbo Cancer Hospital
Ningbo Cancer Hospital clinical programs — 120 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 120
- Drugs
- 183
- Patents
- 0
Ningbo Cancer Hospital projects
120 ClinicalTrials.gov programs sponsored by Ningbo Cancer Hospital.
Ningbo Cancer Hospital has 120 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
UC-0140/1711_UCBG3
Ningbo Cancer Hospital
Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.
1 trial -
UC-0140/1812
Ningbo Cancer Hospital
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.
1 trial -
UC-0150/1704
Ningbo Cancer Hospital
Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).
1 trial -
UC-BCG-2011
Ningbo Cancer Hospital
HER2+ metastatic breast cancer with isolated brain progression
1 trial -
UC-BCG-2103
Ningbo Cancer Hospital
Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse
1 trial -
UC-BCG-2211, CAPPA
Ningbo Cancer Hospital
Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.
1 trial -
UC-BCG-2312
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
UC-BCG-2513
Ningbo Cancer Hospital
Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.
1 trial -
UC-GIG-2023
Ningbo Cancer Hospital
Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma
1 trial -
UC-GIG-2308
Ningbo Cancer Hospital
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment
1 trial -
UC-GIG-2311
Ningbo Cancer Hospital
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication
1 trial -
UC-GIG-2404
Ningbo Cancer Hospital
Advanced biliary tract cancer (BTC)
1 trial -
UC-GIG-2411
Ningbo Cancer Hospital
Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)
1 trial -
UC-GMP-2504
Ningbo Cancer Hospital
Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting
1 trial -
UC-IMM-2302
Ningbo Cancer Hospital
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer
1 trial -
UC-IMM-2509/2510
Ningbo Cancer Hospital
NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.
1 trial -
UC-IMM-2511/2512
Ningbo Cancer Hospital
METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)
1 trial -
UC-SAR-2212_L-UteCIN
Ningbo Cancer Hospital
Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma
1 trial -
UC_0160/1406
Ningbo Cancer Hospital
Penis carcinoma
1 trial -
Verzenios 50 mg film-coated tablets
Ningbo Cancer Hospital
High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.
1 trial -
Zelboraf 240 mg film-coated tablets
Ningbo Cancer Hospital
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment
1 trial -
CTRIAL-IE 19-17
Ningbo Cancer Hospital
Relapsed/ refractory multiple myeloma
1 trial -
GEICAM/2023-09
Ningbo Cancer Hospital
Early Breast Cancer
1 trial -
SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation
Ningbo Cancer Hospital
Gastroenteropancreatic neuroendocrine tumors
1 trial
Frequently asked questions
How many clinical projects does Ningbo Cancer Hospital have?
120 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.